If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2024

Research Output 2008 2018

11 Citations (Scopus)

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., 1 Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.

Research output: Contribution to journalArticleResearchpeer-review

mTOR inhibition beyond rapalogs

Markman, B., Serra, V. & Tabernero, J., 2016, mTOR Inhibition for Cancer Therapy: Past, Present and Future. Mita, M., Mita, A. & Rowinsky, E. K. (eds.). Paris France: Springer, p. 251 - 27 25 p.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

64 Citations (Scopus)

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., Miles, D. & LoRusso, P. M., 2014, In : Clinical Cancer Research. 20, 9, p. 2445 - 2456 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
28 Citations (Scopus)

PI3K pathway inhibitors: better not left alone

Markman, B., Tao, J. J. & Scaltriti, M., 2013, In : Current Pharmaceutical Design. 19, 5, p. 895 - 906 12 p.

Research output: Contribution to journalArticleResearchpeer-review